MYHERITAGE
26.1.2021 08:41:12 CET | Business Wire | Pressemeddelelse
MyHeritage , den førende globale tjeneste til at opdage din fortid og tage kontrol over din fremtid, annoncerede i dag udgivelsen af farvegendannelse til falmede farvefotos. En væsentlig forbedring af MyHeritages avancerede pakke af fotoværktøjer. Farvegendannelse genopliver de autentiske farver i falmede fotos med exceptionelle resultater.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20210125005981/da/
Farvegendannelse er ideel til gamle farvefotos fra 1950'erne til 1990'erne, hvor kemien af trykte fotos gemt i album ikke stod tidens prøve og fik farverne til at falme eller blive gule. Teknologien til farvegendannelse blev udelukkende licenseret fra DeOldify, skabt af eksperter inden for deep learning, Jason Antic og Dana Kelley, og blev integreret i MyHeritage. Det gendanner nøjagtigt et fotos originale farver og og gør på samme tid billedet skarpere. Farvegendannelse er en kraftfuld ny tilføjelse til MyHeritage In Color™ , virksomhedens flagskibsfotofunktion til farvelægning af sort-hvid fotos, som også blev udviklet af DeOldify og udelukkende licenseret af MyHeritage.
MyHeritage In Color™ og en anden AI-baseret funktion, MyHeritage Photo Enhancer , blev udgivet sidste år og er blevet brugt af forbrugere over 20 millioner gange. Begge er gået virale, har modtaget stor anerkendelse og inspireret en fornyet påskønnelse af historiske fotos blandt forbrugerne.
”I 2020 blev MyHeritage den bedste online destination for farvelægning, forbedring og deling af historiske fotos,” sagde Gilad Japhet, grundlægger og administrerende direktør for MyHeritage. ”Tilføjelsen af farvegendannelse til vores robuste serie af fotofunktioner, giver den utrolige mulighed for at bringe værdsatte barndomsminder tilbage i live og dele de smukt genoplivede fotos med vores familie og venner. Nostalgi bliver ikke bedre end dette!”
"Vi er begejstrede over, at vores banebrydende farvegendannelsesmodel vil blive nydt af fællesskabet som en del af MyHeritage In Color™", sagde Jason Antic og Dana Kelley, grundlæggere af DeOldify. "Det har været en stor indsats at skabe denne software, og vi kan ikke komme i tanke på en bedre partner til at bringe den på markedet end MyHeritage, et firma, der er defineret af innovation, og hvis mission er at gøre slægtshistorie mere tilgængelig for mennesker overalt i verden."
Integration i MyHeritage-platformen
Millioner af mennesker over hele verden bruger MyHeritage-platformen til at opdage deres slægtshistorie og bevare deres familiefotos digitalt. Med teknologier i verdensklasse til farvelægning og forbedring af fotos og med tilføjelsen af farvegendannelse, tilbyder MyHeritage banebrydende værktøjer, der giver nye perspektiver til slægtshistorie.
Farvegendannelse er tilgængelig på MyHeritage-platformen på nettet og i MyHeritages gratis mobilapp til iOS og Android. Mobilappen indeholder en indbygget scanner, så brugerne kan digitalisere familiefotos, der er gemt i fysiske album. Når et foto uploades til MyHeritage, afgører systemet automatisk, om fotoet er sort-hvidt (eller sepia) eller oprindeligt taget i farve. Fotos, der oprindeligt var sort-hvide, kan farvelægges, og de, der er taget i farve, kan få deres originale farver gendannet. Farvegendannede fotos kan let deles med familie og venner på Facebook, Twitter, WhatsApp og andre sociale medier. Gendannelse af farver ændrer ikke fotoet, men opretter en separat kopi på MyHeritage sammen med originalen.
MyHeritage In Color™ er en freemium-funktion på MyHeritage. Brugere kan gendanne farverne på 10 fotos gratis, hvorefter fortsat brug kræver et abonnement.
Om MyHeritage
MyHeritage er den førende globale platform til at opdage og udforske slægtshistorie. Med milliarder af historiske optegnelser og slægttræsprofiler og med sofistikerede matching-teknologier på tværs af alle dens aktiver, giver MyHeritage brugere mulighed for at opdage deres fortid og tage kontrol over deres fremtid. MyHeritage DNA blev lanceret i 2016 og er blevet en af verdens største forbruger-DNA-databaser med 4,7 millioner kunder. Siden 2020 er MyHeritage hjemsted for verdens bedste teknologier til forbedring og farvelægning af historiske fotos. MyHeritage er den mest populære tjeneste for DNA-tests og slægtshistorie i Europa. www.myheritage.dk
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210125005981/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum